| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy, Vol 41, 11-18, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy
BD Cookson
Mupirocin was introduced into clinical practice in the UK in 1985, and has
proved to be an extremely effective treatment of skin infections and one of
the most successful topical antibiotics for the clearance of nasal
Staphylococcus aureus isolates including those resistant to methicillin. It
is currently registered for use in more than 90 countries worldwide.
Unfortunately resistance was described shortly after its initial use. Many
of the issues regarding its use are reviewed here, together with the
mechanisms, genetics, surveillance and epidemiology of resistance,
particularly in staphylococci. The various factors that increase resistance
and how they might be controlled are also discussed.
REVIEWS
The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice
Laboratory of Hospital Infection, PHLS Central Public Health Laboratory, London, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Babu, V. Rekasius, J. P. Parada, P. Schreckenberger, and M. Challapalli Mupirocin Resistance among Methicillin-Resistant Staphylococcus aureus-Colonized Patients at Admission to a Tertiary Care Medical Center J. Clin. Microbiol., July 1, 2009; 47(7): 2279 - 2280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Daskalaki, J. R. Otero, and F. Chaves Molecular characterization of resistance to mupirocin in methicillin-resistant Staphylococcus aureus isolates in a tertiary hospital in Spain J. Antimicrob. Chemother., April 1, 2009; 63(4): 826 - 828. [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Simor, T. L. Stuart, L. Louie, C. Watt, M. Ofner-Agostini, D. Gravel, M. Mulvey, M. Loeb, A. McGeer, E. Bryce, et al. Mupirocin-Resistant, Methicillin-Resistant Staphylococcus aureus Strains in Canadian Hospitals Antimicrob. Agents Chemother., November 1, 2007; 51(11): 3880 - 3886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Ellis, M. E. Griffith, D. P. Dooley, J. C. McLean, J. H. Jorgensen, J. E. Patterson, K. A. Davis, J. S. Hawley, J. A. Regules, R. G. Rivard, et al. Targeted Intranasal Mupirocin To Prevent Colonization and Infection by Community-Associated Methicillin-Resistant Staphylococcus aureus Strains in Soldiers: a Cluster Randomized Controlled Trial Antimicrob. Agents Chemother., October 1, 2007; 51(10): 3591 - 3598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Maisch, J. Baier, B. Franz, M. Maier, M. Landthaler, R.-M. Szeimies, and W. Baumler The role of singlet oxygen and oxygen concentration in photodynamic inactivation of bacteria PNAS, April 24, 2007; 104(17): 7223 - 7228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Perez-Roth, C. Lopez-Aguilar, J. Alcoba-Florez, and S. Mendez-Alvarez High-Level Mupirocin Resistance within Methicillin-Resistant Staphylococcus aureus Pandemic Lineages. Antimicrob. Agents Chemother., September 1, 2006; 50(9): 3207 - 3211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Hurdle, A. J. O'Neill, and I. Chopra Prospects for Aminoacyl-tRNA Synthetase Inhibitors as New Antimicrobial Agents Antimicrob. Agents Chemother., December 1, 2005; 49(12): 4821 - 4833. [Full Text] [PDF]
|
|
|
|
|
|
J. G. Hurdle, A. J. O'Neill, L. Mody, I. Chopra, and S. F. Bradley In vivo transfer of high-level mupirocin resistance from Staphylococcus epidermidis to methicillin-resistant Staphylococcus aureus associated with failure of mupirocin prophylaxis J. Antimicrob. Chemother., December 1, 2005; 56(6): 1166 - 1168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. Critchley, C. L. Young, K. C. Stone, U. A. Ochsner, J. Guiles, T. Tarasow, and N. Janjic Antibacterial Activity of REP8839, a New Antibiotic for Topical Use Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4247 - 4252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Rouse, M. Rotger, K. E. Piper, J. M. Steckelberg, M. Scholz, J. Andrews, and R. Patel In Vitro and In Vivo Evaluations of the Activities of Lauric Acid Monoester Formulations against Staphylococcus aureus Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3187 - 3191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rotger, A. Trampuz, K. E. Piper, J. M. Steckelberg, and R. Patel Phenotypic and Genotypic Mupirocin Resistance among Staphylococci Causing Prosthetic Joint Infection J. Clin. Microbiol., August 1, 2005; 43(8): 4266 - 4268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Maisch, C. Bosl, R.-M. Szeimies, N. Lehn, and C. Abels Photodynamic Effects of Novel XF Porphyrin Derivatives on Prokaryotic and Eukaryotic Cells Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1542 - 1552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Lobbedez, M. Gardam, H. Dedier, D. Burdzy, M. Chu, S. Izatt, J. M. Bargman, S. V. Jassal, S. Vas, J. Brunton, et al. Routine use of mupirocin at the peritoneal catheter exit site and mupirocin resistance: still low after 7 years Nephrol. Dial. Transplant., December 1, 2004; 19(12): 3140 - 3143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Hurdle, A. J. O'Neill, E. Ingham, C. Fishwick, and I. Chopra Analysis of Mupirocin Resistance and Fitness in Staphylococcus aureus by Molecular Genetic and Structural Modeling Techniques Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4366 - 4376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Zhang, J. Sparling, B. L. Chow, S. Elsayed, Z. Hussain, D. L. Church, D. B. Gregson, T. Louie, and J. M. Conly New Quadriplex PCR Assay for Detection of Methicillin and Mupirocin Resistance and Simultaneous Discrimination of Staphylococcus aureus from Coagulase-Negative Staphylococci J. Clin. Microbiol., November 1, 2004; 42(11): 4947 - 4955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Tomic, P. Svetina Sorli, D. Trinkaus, J. Sorli, A. F. Widmer, and A. Trampuz Comprehensive Strategy to Prevent Nosocomial Spread of Methicillin-Resistant Staphylococcus aureus in a Highly Endemic Setting Arch Intern Med, October 11, 2004; 164(18): 2038 - 2043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Walker, F. Levy, M. Shorman, G. David, J. Abdalla, and F. A. Sarubbi A Decline in Mupirocin Resistance in Methicillin-Resistant Staphylococcus aureus Accompanied Administrative Control of Prescriptions J. Clin. Microbiol., June 1, 2004; 42(6): 2792 - 2795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. F.L. Wertheim, M. C. Vos, A. Ott, A. Voss, J. A.J.W. Kluytmans, C. M.J.E. Vandenbroucke-Grauls, M. H.M. Meester, P. H.J. van Keulen, and H. A. Verbrugh Mupirocin Prophylaxis against Nosocomial Staphylococcus aureus Infections in Nonsurgical Patients: A Randomized Study Ann Intern Med, March 16, 2004; 140(6): 419 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Chaves, J. Garcia-Martinez, S. de Miguel, and J. R. Otero Molecular Characterization of Resistance to Mupirocin in Methicillin-Susceptible and -Resistant Isolates of Staphylococcus aureus from Nasal Samples J. Clin. Microbiol., February 1, 2004; 42(2): 822 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Petinaki, I. Spiliopoulou, F. Kontos, M. Maniati, Z. Bersos, N. Stakias, H. Malamou-Lada, Ch. Koutsia-Carouzou, and A. N. Maniatis Clonal dissemination of mupirocin-resistant staphylococci in Greek hospitals J. Antimicrob. Chemother., January 1, 2004; 53(1): 105 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Hurdle, A. J. O'Neill, and I. Chopra The isoleucyl-tRNA synthetase mutation V588F conferring mupirocin resistance in glycopeptide-intermediate Staphylococcus aureus is not associated with a significant fitness burden J. Antimicrob. Chemother., January 1, 2004; 53(1): 102 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fujimura, Y. Tokue, and A. Watanabe Isoleucyl-tRNA Synthetase Mutations in Staphylococcus aureus Clinical Isolates and In Vitro Selection of Low-Level Mupirocin-Resistant Strains Antimicrob. Agents Chemother., October 1, 2003; 47(10): 3373 - 3374. [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Yun, S. W. Lee, G. M. Yoon, S. Y. Kim, S. Choi, Y. S. Lee, E.-C. Choi, and S. Kim Prevalence and mechanisms of low- and high-level mupirocin resistance in staphylococci isolated from a Korean hospital J. Antimicrob. Chemother., March 1, 2003; 51(3): 619 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Farr Mupirocin to Prevent S. aureus Infections N. Engl. J. Med., June 13, 2002; 346(24): 1905 - 1906. [Full Text] [PDF]
|
|
|
|
|
|
M. Antonio, N. McFerran, and M. J. Pallen Mutations Affecting the Rossman Fold of Isoleucyl-tRNA Synthetase Are Correlated with Low-Level Mupirocin Resistance in Staphylococcus aureus Antimicrob. Agents Chemother., February 1, 2002; 46(2): 438 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Perez-Fontan, A. Rodriguez-Carmona, M. Rosales, T. Garcia-Falcon, and F. Valdes Incidence and clinical significance of nasal and pericatheter colonization by Gram-negative bacteria among patients undergoing chronic peritoneal dialysis Nephrol. Dial. Transplant., January 1, 2002; 17(1): 118 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E.E. UDO, L.E. JACOB, and B. MATHEW Genetic analysis of methicillin-resistant Staphylococcus aureus expressing high- and low-level mupirocin resistance J. Med. Microbiol., October 1, 2001; 50(10): 909 - 915. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Schmitz, A. C. Fluit, A. Beeck, M. Perdikouli, and C. von Eiff Development of chromosomally encoded resistance mutations in small-colony variants of Staphylococcus aureus J. Antimicrob. Chemother., January 1, 2001; 47(1): 113 - 115. [Full Text] [PDF]
|
|
|
|
|
|
F.-J. Schmitz, A. C. Fluit, D. Hafner, A. Beeck, M. Perdikouli, M. Boos, S. Scheuring, J. Verhoef, K. Köhrer, and C. Von Eiff Development of Resistance to Ciprofloxacin, Rifampin, and Mupirocin in Methicillin-Susceptible and -Resistant Staphylococcus aureus Isolates Antimicrob. Agents Chemother., November 1, 2000; 44(11): 3229 - 3231. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Rodenhuis The Status of High-Dose Chemotherapy in Breast Cancer Oncologist, October 1, 2000; 5(5): 369 - 375. [Abstract] [Full Text]
|
|
|
|
|
|
R. R. S. Nelson Selection of resistance to the essential oil of Melaleuca alternifolia in Staphylococcus aureus J. Antimicrob. Chemother., April 1, 2000; 45(4): 549 - 550. [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Kiser, J. M. Cantey-Kiser, and J. C. Lee Development and Characterization of a Staphylococcus aureus Nasal Colonization Model in Mice Infect. Immun., October 1, 1999; 67(10): 5001 - 5006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Leski, M. Gniadkowski, A. Skoczynska, E. Stefaniuk, K. Trzcinski, and W. Hryniewicz Outbreak of Mupirocin-Resistant Staphylococci in a Hospital in Warsaw, Poland, Due to Plasmid Transmission and Clonal Spread of Several Strains J. Clin. Microbiol., September 1, 1999; 37(9): 2781 - 2788. [Abstract] [Full Text]
|
|
|
|
|
|
S. Harbarth, S. Dharan, N. Liassine, P. Herrault, R. Auckenthaler, and D. Pittet Randomized, Placebo-Controlled, Double-Blind Trial To Evaluate the Efficacy of Mupirocin for Eradicating Carriage of Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., June 1, 1999; 43(6): 1412 - 1416. [Abstract] [Full Text]
|
|